The 19,000-treatment figure — what it means for patients

More than 19,000 ChondroFiller® treatments have been delivered across clinical practice worldwide — a figure spanning multiple countries, joint types, and patient profiles accumulated over more than a decade of use. For anyone weighing an unfamiliar injectable scaffold, that number is the most immediate answer to the question every patient in that position asks: has this been used enough to trust?

The honest answer is that the scale is substantial and genuinely informative, but the figure deserves a clear-eyed reading. It is a cumulative commercial and clinical treatment count, not a prospective safety registry with universal adverse-event reporting. Not every case was enrolled in a formal study with systematic outcome capture. What the available evidence does show, consistently and across diverse applications, is that no serious device-related complication has been reported within this body of use — a finding that holds across published post-market studies as well as the manufacturer's April 2025 Clinical Evaluation Report.

That absence of serious harm, across a dataset of this size, carries real weight. The complication rate recorded across clinical studies sits at approximately 0%, with a reoperation rate of roughly 3–8% — figures that place ChondroFiller® at the more favourable end of the cartilage-repair safety spectrum, even before the procedural advantages of an outpatient injection over open surgery are taken into account.

Why the material itself carries a low complication profile

Three overlapping biological features help explain why a near-zero serious-complication rate makes mechanistic sense, rather than appearing as a statistical anomaly.

Acellular design. ChondroFiller® contains no donor cells — only a purified collagen protein. With no foreign cell antigens present, the immune system has no cellular target to mount a rejection response against, removing a major source of immune-mediated complications and any need for immunosuppressive medication.

Collagen architecture. The murine collagen is extracted through a non-enzymatic, weak-acid process that preserves the telopeptide regions of each molecule. These regions act as natural crosslinking sites, allowing the material to self-assemble into a fibril structure that closely resembles native tissue. Pepsin-digested alternatives strip these sites away; retaining them is considered central to the material's biocompatibility profile.

Biodegradable rather than permanent. Unlike synthetic hydrogels, the scaffold is progressively broken down and replaced by host-derived repair tissue. The joint is not left hosting a permanent foreign material — the long-term implant risks associated with non-degradable fillers do not apply in the same way.

Procedural risk. Delivery as an ultrasound-guided outpatient injection, under local anaesthesia or mild sedation, removes the general or spinal anaesthetic exposure and surgical-site infection risk that accompany arthroscopic procedures.

None of this guarantees an uncomplicated outcome in every individual case. But each feature points in the same direction, and together they give the safety statistics a biologically grounded explanation rather than leaving them as a bare count.

What published studies report

The Jerosch et al. prospective post-market clinical follow-up (PMCF) study provides the most detailed longitudinal safety record currently published. Participants recorded a mean IKDC functional score improvement of 32.4 points — an efficacy finding — but the concurrent safety finding carries equal weight: no device-related serious adverse events were reported across the full three-year observation window. Follow-up scores held steady and edged slightly higher from earlier timepoints, indicating the absence of harm was maintained as the scaffold matured in situ, not only in the immediate post-injection period.

Objective MRI data add a complementary layer. MOCART scores — a standardised assessment of repair-tissue quality — rose from lower values at four weeks to between 81.6 and 84.3 at one year in European clinical series. That trajectory reflects progressive scaffold remodelling into integrated repair tissue, not a static fill or worsening foreign-body response. Scores above 80 indicate good defect filling and tissue continuity by standard MOCART criteria.

Published series extend the safety record well beyond the knee. Perez-Carro et al. (2021) reported hip applications without noting serious device-related adverse events; Corain et al. (2023) found the same pattern in thumb cartilage defects; Matta et al. covered wrist applications on equivalent terms. Each series is relatively small, and all derive from a manufacturer-sponsored or manufacturer-linked evidence base — generalisability should be read in that context. Even so, consistency across anatomically distinct joint environments suggests the safety profile is not specific to a single favourable setting.

Weninger et al. (2025) extend the picture to a more demanding patient group: Grade IV knee defects treated with scaffold plus mesenchymal stem cell co-delivery. No serious device-related adverse events were recorded in this higher-complexity cohort, suggesting the scaffold component maintains its safety characteristics when used as part of a combination approach — though this protocol as a whole has not yet been evaluated in a randomised trial.

How the risk profile compares with surgical cartilage repair

Surgical cartilage repair remains the reference pathway for many patients with focal defects, and published complication data from that landscape place ChondroFiller®'s figures into sharper relief — with one important caveat that must stay visible throughout: the figures below are drawn from the state-of-art literature review within meidrix's Version 09 Clinical Evaluation Report (CER, April 2025), not from independent head-to-head trials.

Microfracture carries a reoperation rate of up to 41% in the CER's reviewed literature — high enough that a substantial proportion of patients require a further procedure within the medium term. Its complication rate, while lower at 0–7% in the same review, comes alongside that elevated secondary-intervention burden.

ACI and MACI show a complication rate reaching 17% and a reoperation rate of up to 37% in the same CER review. MACI also demands two separate surgical episodes — an initial cartilage biopsy, then an implantation procedure weeks later — so a patient accepts two procedural risk windows before any clinical benefit is realised.

OAT / mosaicplasty introduces donor-site morbidity: healthy cartilage and bone must be taken from elsewhere in the joint to fill the defect. That complication category does not arise with a single-site injectable scaffold, because no tissue is harvested.

Against that backdrop, the CER's reported complication rate of approximately 0% and reoperation rate of 3–8% for ChondroFiller® liquid sit at the favourable end of the published range. No independent randomised controlled trial has yet directly compared ChondroFiller® against any of these surgical options with safety as a primary endpoint, so these figures should be read as contextual rather than head-to-head proof of superiority.

The honest residual risk: what a 3–8% reoperation rate means

A 3–8% reoperation rate sits alongside a near-zero serious-complication figure in ChondroFiller®'s Clinical Evaluation Report — and understanding the difference between those two numbers matters for realistic expectations.

Reoperation in this context does not mean a device failure or a serious adverse event. It means a proportion of patients — between three and eight in every hundred, on the CER's own reported figures — required a further procedure at some point during follow-up. That subsequent step might address incomplete defect filling, mechanical factors within the joint, or progression in surrounding cartilage. It is a clinically relevant finding, but a categorically different one from a device-related harm. The near-zero serious adverse-event rate and the 3–8% reoperation rate therefore coexist honestly: they measure different things.

What determines whether an individual patient falls into that minority is not resolvable from a population-level percentage. Defect size, age, joint-loading demands, and the condition of the surrounding cartilage all plausibly influence how completely the scaffold integrates and how the joint responds over time. Published series do not isolate these variables with enough granularity to predict individual outcomes. That assessment — weighing imaging findings, activity profile, and defect characteristics against the realistic range of results — belongs in a clinical consultation, not an article.

Limitations of the current evidence base

One distinction the existing evidence base has not yet resolved concerns combination use. Weninger et al. (2025) report encouraging outcomes when ChondroFiller® is delivered alongside mesenchymal stem cells and platelet-rich fibrin in Grade IV knee defects — a protocol sometimes described as NanoACi — but that combination has not been evaluated as a unified system in a randomised controlled trial. The component elements carry their own separate evidence histories; whether combining them produces additional benefit beyond the scaffold alone, and whether the combined safety profile mirrors that of ChondroFiller® used independently, remains an open question.

That gap has a practical bearing, because patients with the most severe cartilage loss are most likely to be considered for augmented protocols. The evidence underpinning standalone ChondroFiller® is the more mature body of data; evidence for the combined approach is earlier-stage and should be interpreted accordingly.

Taken as a whole, the current safety picture is the best presently available — built across more than a decade and multiple anatomical applications — and points consistently in the same direction. What would consolidate it further is a prospective registry with independent adverse-event adjudication run in parallel with combination-protocol trials, specifically designed to capture whether outcomes and complication rates diverge when MSC co-delivery is added to the scaffold. Until then, patients weighing that augmented pathway are making a decision on promising but preliminary evidence, and any clinical consultation should reflect that difference in evidence maturity.